Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on LOW & BONAR PLC. We currently have 23 research reports from 3 professional analysts.
|16Jan17 12:07||RNS||Second Price Monitoring Extn|
|16Jan17 12:02||RNS||Price Monitoring Extension|
|09Jan17 07:00||RNS||Notice of Results|
|05Jan17 04:42||RNS||Second Price Monitoring Extn|
|05Jan17 04:38||RNS||Price Monitoring Extension|
|04Jan17 12:16||RNS||Holding(s) in Company|
|04Jan17 12:14||RNS||Holding(s) in Company|
Frequency of research reports
Research reports on
LOW & BONAR PLC
LOW & BONAR PLC
N+1 Singer - Morning Song 03-11-2016
03 Nov 16
Overall trading for the year appears to have started slightly slowly overall but with underlying revenues making progress and profits flat for the period. Slow profit progress was already expected due to the previously signalled growth orientated investment being made. A material timing change on a Compliance unit contract, strong growth in AXCO and buoyant Health performance bode well for revenue performance looking forward. Visibility levels are said to be good underpinning managements confidence that the group is on track for the year. Wilmington remains a good play on the growth in global regulation and compliance. BUY
N+1 Singer - Capital Goods - Backdrop suggests upgrades ahead
09 Sep 16
Our latest review of the UK capital goods sector suggests a more positive outlook for our stocks, echoing the more hopeful picture we identified at the start of the year (Best Ideas 2016, 4 January). While growth remains very low, key indicators suggest a slight improvement for our universe by the end of 2016. More significantly, weak sterling is set to provide a materially bigger boost to sales in H2 than in H1 if FX rates are maintained. This does not appear to be reflected in consensus forecasts, which have also seen their first quarterly upgrade in Q3 to date after four years of quarterly downgrades. Share prices have risen sharply through 2016, taking our weighted sector P/E to c.20x. However the sector does not look expensive relative to the market, trading on its normal premium to the FTSE All-Share. To identify the best prospects we have assessed end market commentary from overseas capital goods groups, track records of growth and introduced quant screens relating to profitability and cash generation. Given the more positive tone to our findings, we have a number of Buy recommendations, but only one Sell. In this note we summarise the main inputs into our sector view, along with overviews of our coverage and some interesting non-coverage stocks.
N+1 Singer - Morning Song 09-09-2016
09 Sep 16
Summit continues to make strong progress with its utrophin modulation and C. difficile infection (CDI) programmes. Ezutromid has commenced a Phase II proof-of-concept trial (PhaseOut DMD) in the UK, with the first muscle biopsy data expected Q2/Q3 2017. A placebo controlled trial is expected to start in H2 2017, assuming positive interim data from the PhaseOut DMD trial. Ridinilazole Phase III options are currently being evaluated for CDI and we expect an update later in the year. We remain positive on the group’s future prospects and its significant market potential.
Business improvement in action
02 Aug 16
Significant investment activity, business portfolio management and more favourable financing have all been prominent features in the year to date, with group EBIT progress also delivered in H116. We expect Low & Bonar to deliver solid H2 performance and to continue its strategy of business improvement. Our estimates are modestly higher in the current year, more so in the following two and the FY17e P/E is now below 10x with a dividend yield of c 5%.
First Half 2016 Results
01 Aug 16
The disposal of the Sports and Leisure yarns business is proof that Low & Bonar is intent on delivering its strategy to focus on higher margin markets at the expense of commodity businesses or areas in which it does not have a strong market position. The results for the first half demonstrated that there is now solid potential growth in most areas of operation as European markets continue to stabilise. The company has the potential to leverage its manufacturing expertise and intellectual property in order to expand through a combination of organic growth and selective M&A activity, The current rating is still reflecting historic trading difficulties and the subsequent uncertainties of a new management team and a revised strategy. However, there was sufficient evidence in recent results to suggest that a more optimistic view is now appropriate.
N+1 Singer - Morning Song 07-07-2016
07 Jul 16
On the day of the BREXIT vote result we highlighted our recent Buy upgrade on UBM and its attractive post-vote characteristics. The stock has performed well (c10% total return) since we upgraded to Buy but has more to offer. UBM’s improved mix post the PRN disposal (over 95% of profits from events) and high US$/US$-linked exposure make for an appealing profile in an uncertain environment (at group level no profit was generated in GBP in FY15). We have adjusted our FX and cost assumptions, boosting FY17 EPS by almost 15%. Our events organic growth assumptions look robust at just under 2% in FY16, and 2.8% in FY17 and FY18 yet earnings growth is 23% in FY16 and 26% in FY17. We lift our TP to 685p (was 605p) and reiterate our Buy rating. We suggest taking profits on recent IPO performer Ascential (NR) and Buy UBM thereby switching into more attractive exposure at the same valuation (c11x FY16/17 cycle) and avoiding a potential stock overhang situation.
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
N+1 Singer - Small-cap quantitative research - Momentum screen refresh + 10 focus stocks
12 Jan 17
We have refreshed our momentum style screen for the first time since inception on 26 July 2016. As before, the screen selects the 25 stocks exhibiting the most extreme momentum characteristics, according to our measurement method. From these we have selected 10 to focus on. Since inception the screen has underperformed both the main small-cap and micro-cap indices against a background of generally rising momentum. We have noted a subset of the basket, where decelerating momentum at the time of measurement appears correlated with significant share price falls since selection. We shall monitor this factor with the new screen, albeit there are only two such stocks showing this pattern, namely Lamprell (not rated) and Gear4music (not rated).
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.
N+1 Singer - Morning Song 12-01-2017
12 Jan 17
As anticipated, the second half has again been stronger than H1 and results will be broadly in line with expectations. In line with this, the order book has continued to grow and is at record levels. This confirms that significant progress has been made in the Group’s shift towards its Technology Products division which, as targeted, contributed c.60% of group revenue in FY16. The small acquisition of Cable Power also gives a complementary boost to the product range. It is also worth noting the significant reduction in net debt, £1.0m ahead of our forecast. We remain supportive of the Group’s strategy and continue to see a bright future as this transition towards a design led technology solutions business continues. We look forward to more detail in March at the final results.
Upgrade on positive year-end trading update
10 Jan 17
The group has announced a positive year end update, with a stronger finish to the year delivering sales slightly better than expectations. Operational gearing results in a 7.5% increase in EPS. Cash generation is significantly better than expected. As a result, we increase our price target from 205p to 254p, based on a fair value P/E of 12.0x for 2017. With healthy growth set to carry on, the shares should continue to show robust momentum, with the potential for a special dividend an additional positive.